Eradication of leukemia stem cells by inhibitors of DNA methyltransferase, EZH2 and G9a histone methyltransferases
Main Article Content
Abstract
Complete eradication of leukemic stem cells (LSCs) in patients with acute myeloid leukemia (AML) is required for curative therapy. Epigenetic alterations that involve gene-silencing by DNA methylation by DNMT1, methylation of H3K27 by EZH2 histone methyltransferase (HMT) and methylation of H3K9 by G9a HMT may play a major role in the development of AML. The major action of these epigenetic alterations is the silencing of the genes that program differentiation of AML cells. Inhibitors of DNA and histone methylation have the potential to reverse this block in differentiation. If tumor suppressor genes (TSGs) contain two gene-silencing markers, such as DNA methylation and H3K27me3, they may not be fully reactivated with only an inhibitor of DNA methylation, such as 5-aza-2’-deoxycytidine (5-AZA-CdR), but may also require an inhibitor of EZH2. In support of this model is the synergistic antileukemic action as shown by a colony assay on AML cells using 5-AZA-CdR in combination with 3-deazaneplanocin A (DZNep), a potent inhibitor of EZH2. A similar type of interaction can occur when TSGs are silenced by DNA methylation and the G9a methylation of H3K9me2, a second gene-silencing marker. Treatment of these AML cells with 5-AZA-CdR and BIX01294, an inhibitor of G9a, also results in a synergistic antileukemic action. Leukemic cells that contain 3 different gene-silencing markers: DNA methylation, H3K27me3 and H3K9me2 may require 3 different inhibitors for maximal antineoplastic activity. This result was observed when the AML cells were treated in with 5-AZA-CdR, DZNep and BIX01294. The aim of this study was to demonstrate that epigenetic agents that target DNA and histone methylation have remarkable antineoplastic activity against myeloid leukemia cells. The second aim was to propose a dose-schedule for these epigenetic agents that can be evaluated in a clinical trial in patients with advanced AML for its potential to eradicate LSCs. One of the most sensitive targets for chemotherapeutic intervention in LSCs is the block in differentiation due to gene-silencing by DNA and histone methylation. Epigenetic agents that have the potential to reverse this block merit clinical investigation with high priority.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383(7):650-663.
3. Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2009;28:556–561.
4. Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, et al. DECIDER study team. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients With acute myeloid leukemia: Results of a multicenter, randomized, 2 × 2, phase II trial. J Clin Oncol. 2020; 38:257-270.
5. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol. 2000;183(2):145-154.
6. Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, at al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170(6):1079-1095
7. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, et al. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021;12(1):2607.
8. Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nature Med .2016;22:128-134.
9. Fiskus W, Wang Y, Sreekumar A. et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114:2733-2743.
10. Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L, et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 2014;28:317–327.
11. Savickiene J, Treigyte G, Stirblyte I, Valiuliene G, Navakauskiene R. Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation. Leuk Res. 2014;38(7):822-829.
12. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, at al. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res. 2010;70:6968-6977.
13. Momparler RL, Idaghdour Y, Marquez VE, Côté S, Momparler LF, et al., Synergistic antileukemic action of inhibitors of DNA methylation and histone methylation. Leuk Res. 2012;36:1049-1054.
14. Momparler RL, Côté S, Momparler LF, Idaghdour Y. Inhibition of DNA and histone methylation by 5-aza-2'-deoxycytidine (Decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells. Front Oncol. 2017; 15:7,19.
15. Takeshima H, Wakabayashi M, Hattori N, Yamashita S, Ushijima T. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis. 2015;36:192-201.
16. Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, et al. Transcriptional selectivity of epigenetic therapy in cancer. Cancer Res. 2017;77:470-481.
17. Valeriote F, Lin H. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep. 1975;59:895–899.
18. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30:277-286.
19. Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer. 2008;2:8,128.
20. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Eng J Med. 2013;368:2059-2074.
21. Momparler RL, Côté S, Momparler LF. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). Leuk Res. 2013;37:980-984.
22. Momparler RL, Côté S, Marquez VE, Momparler LF. Comparison of the antineoplastic action of 3-deazaneplanocin-A and inhibitors that target the catalytic site of EZH2 histone methyltransferase. Cancer Rep Rev. 2020;3:1-4.
23. Momparler RL, Côté S, Momparler LF. Epigenetic modulation of self-renewal capacity of leukemic stem cells and implications for chemotherapy. Epigenomes. 2020;4,3.
24. Momparler RL, Côté S, Momparler LF. Enhancement of the antileukemic action of the Inhibitors of DNA and histone methylation: 5-aza-2'-Deoxycytidine and 3-deazaneplanocin-A by Vitamin C. Epigenomes. 2021;24:5,7.
25. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006;125(2):301-313.
26. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39(2):232-236.